Logo image of NVCT

NUVECTIS PHARMA INC (NVCT) Stock Price, Quote, News and Overview

NASDAQ:NVCT - Nasdaq - US67080T1088 - Common Stock - Currency: USD

7.67  -0.06 (-0.78%)

NVCT Quote, Performance and Key Statistics

NUVECTIS PHARMA INC

NASDAQ:NVCT (7/25/2025, 10:15:46 AM)

7.67

-0.06 (-0.78%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High11.8
52 Week Low4.44
Market Cap181.24M
Shares23.63M
Float12.55M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06
IPO02-04 2022-02-04


NVCT short term performance overview.The bars show the price performance of NVCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

NVCT long term performance overview.The bars show the price performance of NVCT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20 -30 -40

The current stock price of NVCT is 7.67 USD. In the past month the price decreased by -0.13%. In the past year, price increased by 11.38%.

NUVECTIS PHARMA INC / NVCT Daily stock chart

NVCT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.48 335.17B
AMGN AMGEN INC 14.69 164.00B
GILD GILEAD SCIENCES INC 14.99 144.33B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.31B
REGN REGENERON PHARMACEUTICALS 12.58 60.20B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.74B
ARGX ARGENX SE - ADR 102.85 36.11B
ONC BEONE MEDICINES LTD-ADR 7.44 31.59B
BNTX BIONTECH SE-ADR N/A 27.38B
SMMT SUMMIT THERAPEUTICS INC N/A 20.66B
INSM INSMED INC N/A 19.85B
NTRA NATERA INC N/A 19.35B

About NVCT

Company Profile

NVCT logo image Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.

Company Info

NUVECTIS PHARMA INC

1 Bridge Plaza, Suite 275

Fort Lee NEW JERSEY US

Employees: 13

NVCT Company Website

NVCT Investor Relations

Phone: 13608377232

NUVECTIS PHARMA INC / NVCT FAQ

What is the stock price of NUVECTIS PHARMA INC today?

The current stock price of NVCT is 7.67 USD. The price decreased by -0.78% in the last trading session.


What is the ticker symbol for NUVECTIS PHARMA INC stock?

The exchange symbol of NUVECTIS PHARMA INC is NVCT and it is listed on the Nasdaq exchange.


On which exchange is NVCT stock listed?

NVCT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NUVECTIS PHARMA INC stock?

11 analysts have analysed NVCT and the average price target is 19.38 USD. This implies a price increase of 152.67% is expected in the next year compared to the current price of 7.67. Check the NUVECTIS PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NUVECTIS PHARMA INC worth?

NUVECTIS PHARMA INC (NVCT) has a market capitalization of 181.24M USD. This makes NVCT a Micro Cap stock.


How many employees does NUVECTIS PHARMA INC have?

NUVECTIS PHARMA INC (NVCT) currently has 13 employees.


What are the support and resistance levels for NUVECTIS PHARMA INC (NVCT) stock?

NUVECTIS PHARMA INC (NVCT) has a support level at 7.66 and a resistance level at 7.84. Check the full technical report for a detailed analysis of NVCT support and resistance levels.


Should I buy NUVECTIS PHARMA INC (NVCT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NUVECTIS PHARMA INC (NVCT) stock pay dividends?

NVCT does not pay a dividend.


When does NUVECTIS PHARMA INC (NVCT) report earnings?

NUVECTIS PHARMA INC (NVCT) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of NUVECTIS PHARMA INC (NVCT)?

NUVECTIS PHARMA INC (NVCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.13).


What is the Short Interest ratio of NUVECTIS PHARMA INC (NVCT) stock?

The outstanding short interest for NUVECTIS PHARMA INC (NVCT) is 21.04% of its float. Check the ownership tab for more information on the NVCT short interest.


NVCT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

NVCT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NVCT. While NVCT has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVCT Financial Highlights

Over the last trailing twelve months NVCT reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 19.86% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -66.87%
ROE -96.22%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-8%
Sales Q2Q%N/A
EPS 1Y (TTM)19.86%
Revenue 1Y (TTM)N/A

NVCT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to NVCT. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners9.95%
Ins Owners46.53%
Short Float %21.04%
Short Ratio17.95
Analysts
Analysts81.82
Price Target19.38 (152.67%)
EPS Next Y4.12%
Revenue Next YearN/A